Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism

Table 2 Interaction between changes of LFC and gender among three groups

	No. of patients	Absolute changes of LFC (%) β (95%CI)	P value*	Interaction test P value
PGZ + LSI vs LSI
Men	50	9.79 (0.37, 19.21)	0.046	0.003
Women	50	− 8.26 (− 17.18, − 0.65)	0.025	0.003
BBR + LSI vs LSI
Men	63	− 1.50 (− 9.38, 6.38)	0.710	0.124
Women	45	− 11.88 (− 21.61, − 2.14)	0.020	0.124
BBR + LSI vs PGZ + LSI
Men	57	− 11.29 (− 18.99, − 3.58)	0.007	0.222
Women	45	− 3.61 (− 13.61, 6.38)	0.483	0.222

Data are shown as means (95% confidence interval). Absolute changes of LFC (%), the difference of the absolute changes of LFC for men or women between the PGZ + LSI and LSI groups, the BBR + LSI and LSI groups, or the BBR + LSI and PGZ + LSI groups. Interaction test P value was assessed by Wald’s test
LFC liver fat content
*P value calculated by linear regression model, difference between two different treatment groups.

ISSN: 2042-6410